...
首页> 外文期刊>BMC Complementary and Alternative Medicine >Efficacy and safety of Si-Jun-Zi-Tang- based therapies for functional (non-ulcer) dyspepsia: a meta-analysis of randomized controlled trials
【24h】

Efficacy and safety of Si-Jun-Zi-Tang- based therapies for functional (non-ulcer) dyspepsia: a meta-analysis of randomized controlled trials

机译:基于Si-jun-Zi-tang的功能性(非溃疡)消化不良的疗效和安全性:随机对照试验的荟萃分析

获取原文
           

摘要

The traditional Chinese medicine formula Si-Jun-Zi-Tang (SJZT) has a long history of application in the treatment of functional dyspepsia (non-ulcer dyspepsia, FD)-like symptoms. SJZT-based therapies have been claimed to be beneficial in managing FD. This study aimed to assess the efficacy and safety of SJZT-based therapies in treating FD by meta-analysis. Systematic searches for RCTs were conducted in seven databases (up to February 2019) without language restrictions. Data were analyzed using Cochrane RevMan software version 5.3.0 and Stata software version 13.1, and reported as relative risk (RR) or odds ratio (OR) with 95% confidence intervals (CIs). The primary outcome was response rate and the secondary outcomes were gastric emptying, quality of life, adverse effects and relapse rate. The quality of evidence was evaluated according to criteria from the Cochrane risk of bias. A total of 341 potentially relevant publications were identified, and 12 RCTs were eligible for inclusion. For the response rate, there was a statically significant benefit in favor of SJZT-based therapies (RR?=?1.23; 95% CI 1.17 to 1.30). However, the benefit was limited to modified SJZT (MSJZT). The relapse rate of FD patients received SJZT-based therapies was lower than that of patients who received conventional medicines (OR?=?0.23; 95% CI 0.10 to 0.51). No SJZT-based therapies-related adverse effect was reported. SJZT-based prescriptions may be effective in treating FD and no serious side-effects were identified, but the effect on response rate appeared to be limited to MSJZT. The results should be interpreted with caution as all the included studies were considered at a high risk of bias. Standardized, large-scale and strictly designed RCTs are needed to further validate the benefits of SJZT-based therapies for FD management. Systematic review registration: [PROSPERO registration: CRD42019139136 ].
机译:中医药公式Si-Jun-Zi-Tang(SJZT)在治疗功能性消化不良(非溃疡性消化不良,FD)的症状中具有悠久的应用历史。基于SJZT的疗法被声称在管理FD方面是有益的。本研究旨在评估SJZT的疗法在治疗FD治疗FD的疗效和安全性。对RCTS的系统搜索在七个数据库中(2019年2月)进行了没有语言限制。使用Cochrane Revman软件5.3.0和Stata软件版本13.1分析数据,并报告为具有95%置信区间(CIS)的相对风险(RR)或赔率比(或)。主要结果是响应率,二次结果是胃排空,生活质量,不良影响和复发率。根据偏倚的Cochrane风险的标准评估证据质量。共识别出341个潜在的相关出版物,12个RCT有资格包含。对于响应率,有一种静态显着的益处,有利于基于SJZT的疗法(RR?=?1.23; 95%CI 1.17至1.30)。然而,利益仅限于修改的SJZT(MSJZT)。 FD患者的复发率接受基于SJZT的疗法低于接受常规药物的患者(或?= 0.23; 95%CI 0.10至0.51)。没有报告基于SJZT的疗法相关的不利影响。基于SJZT的处方可以有效治疗FD并且没有鉴定严重的副作用,但对响应率的影响似乎限于MSJZT。结果应谨慎地解释,因为所有包括的研究都被认为是高风险的偏见。需要标准化,大规模和严格设计的RCT,以进一步验证基于SJZT的疗法的FD管理的疗效。系统审查注册:[Prospero注册:CRD42019139136]。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号